Program Coordinator: Laura Kasman, Ph.D. kasmanL@musc.edu
M&I program currently
17 Ph.D. students 4 MD/Ph.D. students 1 DMD/Ph.D. student 2 Masters students 15 Departmental faculty 40 Total Program faculty
Program Requirements
6 credits in advanced M&I courses in 2nd year Written qualifying exam, summer after 2nd year
Thesis proposal defense, usually sometime in 3rd year for admission to candidacy
12 advanced credits total, not including M&I Seminar
M&I Advanced course offerings
Offered Every Y ear FALL MBIM 613G Infec tion MBIM 614G Immunity MBIM 905 Translational Genomic s MBIM 770 Seminar SPRING MBIM 623G Dental Mic robiology MBIM 702 Oral Immunobiology M&I Selec tive MBIM 770 Seminar
Offered ac ademic c yc les beginning in odd years: 2007, 2009, 2011... MBIM 742 Advanc ed Mic robiology MBIM731 Advanc ed Topic s in Immunology
Offered ac ademic c yc les beginning in even years: 2008, 2010, 2012... MBIM 725 Virology MBIM 775 Spec ial Topic s MBIM 772 Environmental Mic ro MBIM 775A Bioentrepreneurship MBIM 779 Immunogenetic s
Departmental vs. Program Faculty
Department Faculty have M&I as their home department M&I Program Faculty can be faculty members from any MUSC department that have research interests related to microbiology or immunology Faculty can be affiliated with more than one graduate program
M&I Department Faculty Interests
ba cte riology virology immunology ge ne thera py
Bacteriologists
Michael Schmidt
Hal May
Ed Balish
Virologists
Natalie Sutkowski
John Y. Dong
Laura Kasman
Immunologists
Janardan Stephen Gabriel Pandey Tomlinson Virella
Aziz Haque
Carl Atkinson
Also Natalie Sutkowski
Tumor Immunologists & Gene Therapy
James Norris Christina Xiang Liu Voelkel-Johnson
Semyon Rubinchik
Also Stephen Tomlinson & John Dong
Program Faculty
Surgery Prabhakar Baliga Mike Nishimura Kenneth Chavin David Cole Yi Zhang Pathology Amanda LaRue
Otolaryngology Rita Young
Neurosciences/Neurology Narendra Banik Narayan Bhat James Cook William Tyor Swapan Ray
Pediatrics Inderjit Singh Isabel Virella-Lowell
Program Faculty
College of Dental Medicine Robert Boackle Caroline Westwater Radiation Oncology Sebastiano Gattoni-Celli College of Pharmaceutical Sciences Craig Beeson Cell Biology & Anatomy Titus Reaves
Rheumatology James Oates Maria Trojanowska Gary Gilkeson Biochemistry Greg Warr Maurizio Del Poeta
Division of Infectious Disease Christopher Parsons
Entrepreneurship by M&I faculty
Company Faculty
Dr. Dong
Dr. Norris Dr. Tomlinson
Technology
Adenovirus-based subunit vaccines
Ceramide-modifying anti-cancer agents Therapeutic complement inhibitors
GenPhar SphingoGene
Taligen
MFC Tech
Dr. May
Bacterial electricity generation, Microbial fuel cells
MOUNT PLEASANT, SC (AUGUST 30, 2007) - Groundbreaking ceremony for new facility at Innovation Park, in the economic development zone of The Market at Oakland.
GenPhar, Inc. is a biopharmaceutical company dedicated to providing vaccines that protect against infectious diseases with great socio-economic impacts worldwide. Biodefense programs: GenPhar's vaccine platform is ideally designed for biodefense because one vaccine can prevent infection from multiple virus subtypes.
SphingoGene, Inc.
OH 2 OH 1 3 4 5
NH CO
n (2S, 3R, 4E) D-erythro -Ceramide
James S. Norris, PhD Co-Founder, SphingoGene, Inc. http://www.sphingogene.com Professor and Chairman, MUSC norrisjs@musc.edu
SphingoGene, Inc. is focused on commercialization of small molecule therapeutics that modify ceramide metabolism to overcome resistance to chemo and radiation therapy and promote apoptosis in cancer cells. Ceramide is a “tumor suppressor sphingolipid” involved in regulation of cell death. SphingoGene, Inc.’s molecules are rationally designed and proven to inhibit enzymes that create resistance to conventional cancer therapies. Our goal is to utilize these small molecules in combination with “standard of care” radiation or chemotherapy to enhance cancer cell death.
Products and Services
Commercial Lipidomic Services Molecular diagnostic to predict patient Response
Combination therapy for standard of care Therapies in cancer patients (chemo, radiation and gene therapy
Stephen Tomlinson, PhD Professor tomlinss@musc.edu
Controlling Inflammation to Treat Human Disease Applying novel technologies to create better treatments Contact: Woodruff Emlen MD wemlen@taligentherapeutics.com Taligen Therapeutics, Inc. is a development stage biotechnology company with novel technology to modulate and regulate activation of the complement system. Inappropriate complement activation leading to inflammation is a major contributor to a large number of human diseases.
Taligen has proof of concept data in animal models of diseases as diverse as asthma, macular degeneration, immune renal disease, inflammatory arthritis, ischemia-reperfusion injury, stroke and traumatic brain injury.
Product Development Currently focused on the areas of asthma and age related macular degeneration.
Microbially Generated Electricity
24/7 Remote Power, Sensor Control
Increase Biofuel Production
Dr. Hal May, Ph.D. VP, MFC Technologies LLC http://www.mfctech.net hmay@mfctech.net Assoc. Prof. MUSC mayh@musc.edu
Control Waste, Odor and Algae
MFC Tech is focused on the development of microbial fuel cell technology (MFCs), which utilizes the ability of bacteria to generate electricity. Patentable approaches are targeted for the enhancement of waste management and electricity generation, namely…
24/7 remote power generation such as along highways and in retention ponds Development of specific sensors or the powering of sensors in remote locations Enhancement of biofuel production through the application of MFC technology to cellulosic ethanol fermentation The reduction of agricultural waste, odors and algal blooms in waste lagoons and retention ponds